Clazosentan for cerebral vasospasm prevention in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.

ABSTRACT:

Background

Aneurysmal subarachnoid hemorrhage (aSAH) remains a devastating neurological emergency, with cerebral vasospasm contributing significantly to poor outcomes. Clazosentan, a selective endothelin-A receptor antagonist, has shown potential in preventing vasospasm, though its overall efficacy and safety profile require comprehensive assessment.

Methods

We conducted a systematic review and meta-analysis following PRISMA guidelines, searching multiple databases through March 2025. We included randomized controlled trials and observational studies comparing clazosentan with placebo or active controls in aSAH patients. Outcomes included vasospasm incidence, its complications, and adverse events.

Results

Analysis of 13 reports (n = 5,728) were included. Compared to p

SUBMITTER: Abunada S 

PROVIDER: S-EPMC12502126 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature